Lipidsenkende Therapie zur Sekundärprävention der peripheren arteriellen VerschlusskrankheitEinfluss der neuen Leitlinien der Europäischen Gesellschaft für Kardiologie/Europäischen Atherosklerose Gesellschaft (ESC/EAS)Lipid-lowering treatment for secondary prevention of peripheral arterial occlusive diseaseInfluence of the new guidelines of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS)

被引：0

作者：

J. F. Dopheide

H. Drexel

机构：

[1] Inselspital Bern,Schweizer Herz

[2] Private Universität im Fürstentum Liechtenstein, und Gefässzentrum

[3] Drexel University College of Medicine,Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) A

来源：

Gefässchirurgie | 2020年 / 25卷 / 3期

关键词：

PAVK; Sekundärprävention; Fettstoffwechselstörungen; Atherosklerose; LDL-Cholesterin; PAOD; Secondary prevention; Dyslipidemia; Atherosclerosis; LDL-cholesterol;

D O I：

10.1007/s00772-020-00629-0

中图分类号：

学科分类号：

摘要：

Fettstoffwechselstörungen gehören neben Bluthochdruck, Rauchen und Diabetes mellitus zu den primären Risikofaktoren, die die Entstehung und den Verlauf der peripheren arteriellen Verschlusskrankheit (PAVK) maßgeblich beeinflussen. Die zentrale Bedeutung der Behandlung der Fettstoffwechselstörungen, insbesondere die Senkung des LDL-Cholesterins (LDL-C), wird in den aktuellen Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC)/Europäischen Atherosklerose Gesellschaft (EAS) noch einmal besonders hervorgehoben.

引用

页码：160 / 165

页数：5

共 55 条

[1]

Aboyans V(2018)2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Soc

[2]

Ricco J-B(2014)Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease JAHA 3 e000697-1446

[3]

Bartelink M-LEL(2018)Association of Statin dose with amputation and survival in patients with peripheral artery disease Circulation 137 1435-1357

[4]

Armstrong EJ(2010)Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis JAMA 304 1350-22

[5]

Chen DC(2019)Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia N Engl J Med 380 11-e92

[6]

Westin GG(2009)Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry Atherosclerosis 204 e86-3058

[7]

Arya S(2016)2016 ESC/EAS guidelines for the management of dyslipidaemias Eur. Heart J. 37 2999-1681

[8]

Khakharia A(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials Lancet 376 1670-386

[9]

Binney ZO(1992)Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 381-416

[10]

Bhatt DL(1997)Antioxidants and atherosclerotic heart disease N Engl J Med 337 408-717

← 1 2 3 4 5 6 →